3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Hodgkin Disease
33
Lymphoma
17
Lymphoma, Large-Cell, Anaplastic
15
Hematologic Diseases
13
Lymphoma, Non-Hodgkin
10
Recurrence
9
Lymphoma, T-Cell
7
Lymphoma, T-Cell, Peripheral
6
Lymphoma, Large B-Cell, Diffuse
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, B-Cell
4
Neoplasms
3
Mycosis Fungoides
3
Lymphoma, T-Cell, Cutaneous
3
Lymphatic Diseases
3
Leukemia
3
Immunoblastic Lymphadenopathy
3
Sezary Syndrome
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Lymphoma, Extranodal NK-T-Cell
2
Leukemia, Myeloid, Acute
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Enteropathy-Associated T-Cell Lymphoma
2
Waldenstrom Macroglobulinemia
1
Testicular Neoplasms
1
Nonseminomatous germ cell tumor
1
Interventions
Carboplatin
23
Cisplatin
19
pembrolizumab
14
Paclitaxel
12
Gemcitabine
12
Pemetrexed
11
130-nm albumin-bound paclitaxel
9
Everolimus
8
Cetuximab
8
Fluorouracil
7
Axitinib
6
osimertinib
5
durvalumab
5
Sunitinib
5
Radiotherapy
5
Erlotinib Hydrochloride
5
Docetaxel
5
Cyclophosphamide
5
Albumin-Bound Paclitaxel
5
Sorafenib
4
Radiation
4
Nivolumab
4
Ipilimumab
4
vosaroxin
3
Radiotherapy, Intensity-Modulated
3
Octreotide
3
Irinotecan
3
Bevacizumab
3
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
3
pralsetinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma
×
Brentuximab Vedotin
×
Clear all
No trials found.